These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease: the emerging potential of RNA interference therapeutics. Swerdlow DI; Rider DA; Yavari A; Wikström Lindholm M; Campion GV; Nissen SE Cardiovasc Res; 2022 Mar; 118(5):1218-1231. PubMed ID: 33769464 [TBL] [Abstract][Full Text] [Related]
14. Role of lipoprotein(a) in atherosclerotic cardiovascular disease: A review of current and emerging therapies. Alhomoud IS; Talasaz A; Mehta A; Kelly MS; Sisson EM; Bucheit JD; Brown R; Dixon DL Pharmacotherapy; 2023 Oct; 43(10):1051-1063. PubMed ID: 37464942 [TBL] [Abstract][Full Text] [Related]
15. Lipoprotein(a): novel target and emergence of novel therapies to lower cardiovascular disease risk. Tsimikas S Curr Opin Endocrinol Diabetes Obes; 2016 Apr; 23(2):157-64. PubMed ID: 26825471 [TBL] [Abstract][Full Text] [Related]
16. Latest developments in the treatment of lipoprotein (a). Bos S; Yayha R; van Lennep JE Curr Opin Lipidol; 2014 Dec; 25(6):452-60. PubMed ID: 25318824 [TBL] [Abstract][Full Text] [Related]
17. Pharmacotherapy for children with elevated levels of lipoprotein(a): future directions. de Boer LM; Wiegman A; Swerdlow DI; Kastelein JJP; Hutten BA Expert Opin Pharmacother; 2022 Oct; 23(14):1601-1615. PubMed ID: 36047306 [TBL] [Abstract][Full Text] [Related]
18. The Promise of PCSK9 and Lipoprotein(a) as Targets for Gene Silencing Therapies. Chan DC; Watts GF Clin Ther; 2023 Nov; 45(11):1034-1046. PubMed ID: 37524569 [TBL] [Abstract][Full Text] [Related]